Science article - April 27, 2019
A paradigm-shift in cancer?
Immunotherapy is the 2016 Clinical Cancer Advance of the Year and a promising new strategy for treating cancer. But how far have we come? The American Society of Clinical Oncology (ASCO) justified this year’s choice of Clinical Cancer Advance, immunotherapy, by the fact that no recent advance has been more transformative, particularly over this past […]
Clinical Trials - March 11, 2019
First patient dosed in Alligator trial
The first patient has successfully been dosed in the company’s phase I study of ATOR-1015, its drug candidate in development for tumor-directed immunotherapy. ATOR-1015 is designed with properties that shall enable it to accumulate in the tumor area after an intravenous injection, and selectively exert its effect there, states the company in their press release. […]
In a new job - November 5, 2014
Targovax Names New CEO
Gunnar Gårdemyr has been named the new CEO of Norwegian company Targovax, effective Jan. 12, 2015. Gårdemyr has spent 30 years in the international pharmaceutical and biotech industries and brings experience in management, business development, mergers and acquisitions, global marketing and commercial strategy to Targovax. Currently he is the corporate advisor for Acino Pharma in […]
